Levosert afleveringsysteem voor intra-uterien gebruik 20 microgram/24 uur
As listed in the register: Levosert afleveringsysteem voor intra-uterien gebruik 20 microgram/24 uur
20 microgram · afleveringsysteem voor intra-uterien gebruik
- Prescription only
- Urinary and reproductive system, hormones
- Active substance
- Levonorgestrel
- Made by
- BModesto B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Skyla). It describes the substance, not this exact product.
The local mechanism by which continuously released LNG contributes to the contraceptive effectiveness of Skyla has not been conclusively demonstrated.
Studies of Skyla and similar LNG IUS prototypes have suggested several mechanisms that prevent pregnancy: thickening of cervical mucus preventing passage of sperm into the uterus, inhibition of sperm capacitation or survival, and alteration of the endometrium.
Following absorption, LNG is extensively metabolized.
About 45% of LNG and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-03-04
Safety of the active substance
From the US prescribing label for the same active substance (Skyla). It describes the substance, not this exact product.
- The use of Skyla is contraindicated when one or more of the following conditions exist:.
- Pregnancy or suspicion of pregnancy [see Warnings and Precautions ( 5.2 ), Use in Specific Populations ( 8.1 )].
- For use as post-coital contraception (emergency contraception).
- Congenital or acquired uterine anomaly including fibroids, that distorts the uterine cavity.
The most common adverse reactions reported (>10% users) are bleeding pattern alterations, vulvovaginitis, abdominal/pelvic pain, acne/seborrhea, headache/migraine, ovarian cyst and dysmenorrhea/uterine spasm.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | BModesto B.V. |
|---|---|
| Active substance | Levonorgestrel |
| Used in | Urinary and reproductive system, hormones |
| Strength | 20 microgram |
| Form | afleveringsysteem voor intra-uterien gebruik |
| Classification | G02BA03 · Urinary and reproductive system, hormones |
| Route | intra-uterien gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| RVG | 136382//126673 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).
Other strengths and forms
3 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- afleveringsysteem voor intra-uterien gebruik3 products
20 microgram3
20 microgram · 3 companies
- BModesto B.V. · this page
- Euro Registratie Collectief B.V.
- Gedeon Richter Plc
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.